New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on Wednesday, signalling that patients are unlikely to get access following approval by the country's medicines regulator.
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients.
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and taxpayers.
UK's medicines regulator approves Lilly's drug for early Alzheimer's
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, the company said on Wednesday. Britain is the third major market where donanemab,
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...
FOX 13 Seattle on MSN7h
Alzheimer's study in Seattle makes new findings for future therapies
In the heart of Seattle, some of the world’s most brilliant minds study the brain at the Allen Institute, where researchers ...
Psychology Today2d
Early Signs of Alzheimer’s Disease? Follow the Money
As our family members age, we worry. We worry about their physical health and potential cognitive declines. If you are ...
Alzheimer's disease may damage the brain in two phases
Alzheimer's disease may damage the brain in two distinct phases, based on new research using sophisticated brain mapping ...
New Alzheimer’s research reveals ‘quiet’ phase of the disease, before symptoms appear
New details have emerged into how Alzheimer’s disease affects the brain. Researchers have identified cellular changes in the ...
ScienceAlert on MSN4d
Alzheimer's Disease Harms The Brain in 2 Distinct Phases, Study Reveals
An analysis of the genetic activity of brain cells in individuals who have died with Alzheimer's disease has revealed the ...
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...
EurekAlert!2d
RPI Alzheimer’s disease research program gets multimillion-dollar boost
Rensselaer Polytechnic Institute (RPI) has been awarded two grants by the National Institute on Aging (NIA) to train graduate ...
Alzheimer's disease might damage brain in two phases
Alzheimer's disease might damage the brain in two distinct phases, a new study suggests. An early phase that occurs slowly ...
Clinical trials sparking hope for Alzheimer's patients: ‘Holding my own'
A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...